What can we learn from this study? And in your practice, do you foresee anyone getting PCI?

So that was a highly anticipated trial presentation recently presented at the World Lung Conference in Korea.

It was about 304 patients that were looked at, including limited stage and extensive stage, looking at this question of PCI versus MRI surveillance.

But the MRI surveillance in this trial was really rigorous.

It was every three months MRI, which in some practices is hard to achieve.

And then later on in the second year, less often.

But Today, for our patients that are coming to our tertiary cancer center, many of them, when we discussed these options and we found that the Maverick trial didn't show a difference in survival, we are very confident with the MRI surveillance.

Getting this patient through chemoimmunotherapy, are you using Trialociclib upfront for all comers? What data do we have for this?